Search
Search
Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD
Show Description +
When it comes to Wet AMD and DME, patients and clinicians face a handful of challenges in disease management. How do providers set treatment goals? Are their goals different for DME compared with Wet AMD? And what obstacles do providers face when managing these patients? Join Diana V. Do, MD, as she moderates a roundtable on these topics. The roundtable is comprised of retina specialists Esther L. Kim, MD; Charles C. Wykoff, MD, PhD; and David S. Chin Yee, MD.
Posted: 11/13/2023
Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD
When it comes to Wet AMD and DME, patients and clinicians face a handful of challenges in disease management. How do providers set treatment goals? Are their goals different for DME compared with Wet AMD? And what obstacles do providers face when managing these patients? Join Diana V. Do, MD, as she moderates a roundtable on these topics. The roundtable is comprised of retina specialists Esther L. Kim, MD; Charles C. Wykoff, MD, PhD; and David S. Chin Yee, MD.
Posted: 11/13/2023
Contemporary Challenges to Treating Wet Age-related Macular Degeneration and Diabetic Macular Edema
About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
Visit us online: regeneron.com
Follow Regeneron
Copyright © 2023 Regeneron Pharmaceuticals Inc. All rights reserved.
10/2023
US.OPH.23.09.0002
_1704488209.png?auto=compress,format&w=180)
_1704488282.png?auto=compress,format&w=180)